^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
TheraPrint® test

Company:
Agendia
Type:
Laboratory Developed Test
Related tests:

Details

Evidence
News
TheraPrint is a microarray-based gene expression panel of 125 genes identified as potential targets for prognosis and therapeutic response. These genes may hold the key to a greater level of personalized prognosis and therapy for BC pts. It provides an individualized genomic fingerprint of the patient’s tumor and correlates the results with a likely response to a variety of hormonal, chemo and biological therapies.
Cancer:
Breast Cancer
Gene:
BCL2 (B-cell CLL/lymphoma 2), BRAF (B-raf proto-oncogene), CCND1 (Cyclin D1), EGFR (Epidermal growth factor receptor), EPHA2 (EPH receptor A2), ERBB4 (erb-b2 receptor tyrosine kinase 4)
See More ...
Method:
Immunohistochemistry (IHC)